Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Buse

Showing results (21-30 of 457) with videos related to

Pageof 46
Sort By:
Diabetes Care|August 21, 2021
Further RISE'ing to the Challenge of Type 2 Diabetes in YouthKlara R Klein, John B Buse
The New England Journal of Medicine|November 16, 2017
Safety of Degludec versus Glargine in Type 2 DiabetesSteven P Marso, John B Buse
Diabetes Care|July 22, 2018
Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia PreventionAnna R Kahkoska, John B Buse
Lancet (London, England)|September 16, 2014
GLP-1 receptor agonists and basal insulin in type 2 diabetesLaura A Young, John B Buse
Nature Reviews. Endocrinology|October 21, 2020
The trials and tribulations of determining HbA<sub>1c</sub> targets for diabetes mellitusKlara R Klein, John B Buse
Diabetologia|July 16, 2020
Real-world evidence: the devil is in the detailMugdha Gokhale, Til Stürmer, John B Buse
Experimental Physiology|January 28, 2021
Experimental increase of blood glucose alters resting state EEG measures of excitation-inhibition balanceChristopher P Walker, John B Buse, Flavio Frohlich
JAMA Internal Medicine|December 6, 2017
Concerns About Conclusions of Self-monitoring of Blood Glucose-ReplyLaura A Young, John B Buse, Katrina E Donahue
Diabetes/Metabolism Research and Reviews|July 24, 2009
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP)Kathleen M Dungan, John B Buse, Robert E Ratner
Diabetes Care|January 29, 2005
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen changeRichard W Grant, John B Buse, James B Meigs, et al.
Pageof 46

Showing results (21-30 of 457) with videos related to

Sort By:
Pageof 46
Diabetes Care|August 21, 2021
Further RISE'ing to the Challenge of Type 2 Diabetes in YouthKlara R Klein, John B Buse
The New England Journal of Medicine|November 16, 2017
Safety of Degludec versus Glargine in Type 2 DiabetesSteven P Marso, John B Buse
Diabetes Care|July 22, 2018
Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia PreventionAnna R Kahkoska, John B Buse
Lancet (London, England)|September 16, 2014
GLP-1 receptor agonists and basal insulin in type 2 diabetesLaura A Young, John B Buse
Nature Reviews. Endocrinology|October 21, 2020
The trials and tribulations of determining HbA<sub>1c</sub> targets for diabetes mellitusKlara R Klein, John B Buse
Diabetologia|July 16, 2020
Real-world evidence: the devil is in the detailMugdha Gokhale, Til Stürmer, John B Buse
Experimental Physiology|January 28, 2021
Experimental increase of blood glucose alters resting state EEG measures of excitation-inhibition balanceChristopher P Walker, John B Buse, Flavio Frohlich
JAMA Internal Medicine|December 6, 2017
Concerns About Conclusions of Self-monitoring of Blood Glucose-ReplyLaura A Young, John B Buse, Katrina E Donahue
Diabetes/Metabolism Research and Reviews|July 24, 2009
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP)Kathleen M Dungan, John B Buse, Robert E Ratner
Diabetes Care|January 29, 2005
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen changeRichard W Grant, John B Buse, James B Meigs, et al.
Pageof 46